Drug Profile
CMD 004
Alternative Names: CMD-004; HPV-T cellsLatest Information Update: 11 May 2021
Price :
$50
*
At a glance
- Originator Cell Medica
- Developer Kuur Therapeutics
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anal cancer; Cervical cancer; Oropharyngeal cancer
Most Recent Events
- 04 May 2021 Kuur Therapeutics has been acquired by Athenex
- 28 Feb 2021 No recent reports of development identified for preclinical development in Anal-cancer in United Kingdom (Parenteral)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Cervical-cancer in United Kingdom (Parenteral)